Merck's Vioxx Pain Control Is Superior To Endo's Percocet, Reps Tell Doctors
Executive Summary
Merck's attempts to boost the performance of Vioxx include sales rep distribution of data supporting the COX-2 inhibitor's superiority to Endo's Percocet, Senior Director-Investor Relations Laura Jordan told analysts during an Oct. 18 earnings call.
You may also be interested in...
Merck Re-Sets Expectations For 2002: Zocor, Prilosec Are Possible Upsides
Merck's re-calibrated projections for 2002 provide some flexibility for the company if Zocor sales continue to be strong or the launch of generic versions of Prilosec are delayed
Merck COX-2 Cardiovascular Safety Studies Will Enroll 30,000 Subjects
Merck plans to enroll approximately 30,000 subjects in cardiovascular safety trials to resolve issues raised about the CV effects of its COX-2 inhibitors Vioxx (rofecoxib) and Arcoxia (etoricoxib)
Merck Re-Sets Expectations For 2002: Zocor, Prilosec Are Possible Upsides
Merck's re-calibrated projections for 2002 provide some flexibility for the company if Zocor sales continue to be strong or the launch of generic versions of Prilosec are delayed